Stem cell therapy for ACLF progresses to safety, efficacy trial

Promethera Biosciences announced the initiation of a phase 2b clinical trial to evaluate the safety and efficacy of HepaStem, a liver-derived stem cell therapy candidate for patients with acute-on-chronic liver failure, according to a press release.“We are developing HepaStem as a treatment for ACLF at a fast pace and we are determined to bring it to patients in need as soon as we can,” Etienne Sokal, MD, PhD, founder and group chief medical officer of Promethera, said in the release. “As a potentially pivotal trial, the results obtained here may provide us with sufficientRead More

Share on facebook
Share on twitter
Share on linkedin